Legal & General Group PLC Nkarta, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Nkarta, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,567 shares of NKTX stock, worth $11,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,567

Previous 4,567 -0.0%

Holding current value

$11,554

Previous $20,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.27 - $10.82 $11,651 - $23,923	2,211 Added 93.85%	4,567 $26,000
Q4 2023 Feb 15, 2024	SELL	$1.31 - $6.6 $945 - $4,765	-722 Reduced 23.46%	2,356 $15,000
Q2 2023 Aug 14, 2023	SELL	$2.19 - $5.17 $777 - $1,835	-355 Reduced 10.34%	3,078 $6,000
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $25,659 - $47,968	-7,614 Reduced 68.92%	3,433 $12,000
Q4 2022 Feb 14, 2023	BUY	$5.14 - $14.35 $39,135 - $109,260	7,614 Added 221.79%	11,047 $66,000
Q3 2022 Nov 14, 2022	BUY	$12.27 - $18.39 $8,613 - $12,909	702 Added 25.7%	3,433 $46,000
Q2 2022 Aug 22, 2022	SELL	$7.77 - $19.44 $7,886 - $19,731	-1,015 Reduced 27.1%	2,731 $34,000
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $9,490 - $19,944	742 Added 24.7%	3,746 $58,000
Q3 2021 Nov 15, 2021	BUY	$26.67 - $38.76 $43,205 - $62,791	1,620 Added 117.05%	3,004 $83,000
Q2 2021 Aug 12, 2021	SELL	$23.94 - $36.68 $23,604 - $36,166	-986 Reduced 41.6%	1,384 $44,000
Q1 2021 May 17, 2021	BUY	$31.33 - $59.61 $9,179 - $17,465	293 Added 14.11%	2,370 $78,000
Q4 2020 Feb 12, 2021	BUY	$27.03 - $75.62 $6,892 - $19,283	255 Added 14.0%	2,077 $128,000
Q3 2020 Nov 13, 2020	BUY	$23.52 - $47.9 $42,853 - $87,273	1,822 New	1,822 $55,000

Others Institutions Holding NKTX

# of Institutions

129

Shares Held

66.5M

Call Options Held

173K

Put Options Held

20K

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $123M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Nkarta, Inc. Transaction History